Jungfraujoch and beyond: high altitude physiology and medicine

Switzerland's innovative strength is recognised worldwide. However, the global competition for AI talent and technologies requires more than just good framework conditions - it needs targeted international networking.

Le Swiss Personalized Health Network (SPHN) est une infrastructure nationale de données placée sous la responsabilité de l’ASSM en collaboration avec le SIB Institut Suisse de Bioinformatique. SPHN rend les données de santé interopérables et réutilisables pour la recherche en Suisse. Pour renforcer l’équipe Ethics, Legal and Social Implications (ELSI), nous cherchons de suite ou pour une date à convenir un.e responsable de projet. Le contrat (60–80%) sera dans un premier temps limité à la fin 2028, avec possibilité de prolongation.

The Lausanne-based company HAYA Therapeutics, featured in the Technology Outlook showcase “The cryptic messages of our genome”, has reached two significant milestones in quick succession: the first cohort of participants has been dosed in a Phase 1 clinical trial of its lead candidate HTX-001, and the company has been named a “Disruptive Pioneer” in the 2026 Global Pharmaceutical Innovation and Invention Index published by IDEA Pharma. These developments underscore the relevance of the technology identified by SATW’s foresight activities.